Biogen Stock Drags On Alzheimer’s Players As FDA Requests Review Of Aduhelm Approval

Biogen’s shares dropped sharply on Friday after the FDA sought an independent assessment of the process that led to the company’s recent Alzheimer’s approval./nRead More